New drug combo shows promise for Hard-to-Treat sarcomas

NCT ID NCT02805725

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two chemotherapy drugs—trabectedin and cyclophosphamide—in 50 adults with advanced soft-tissue sarcomas that had already been treated. The goal was to find a safe dose and see if the combo could stop or slow tumor growth. Results showed the treatment was tolerable and helped some patients avoid progression for at least 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trabectedin and cyclophosphamide
What this could lead to: If successful, this combination could offer a new treatment option to slow or stabilize advanced soft-tissue sarcomas that have not responded to prior therapies.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to all patients. Side effects from the drugs can be serious, and the benefit may be limited to a subset of sarcoma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMAS

Contacts and locations

Locations

Institut Bergonié

Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.